Optimizing Diabetes Mellitus Control with Add-on Therapies to Januvia (Sitagliptin)

Introduction to Add-on Therapies

• The American Diabetes Association recommends metformin as the first-line agent to combine with sitagliptin for better diabetes control, due to its complementary mechanism of action, minimal risk of hypoglycemia, and established efficacy in combination therapy 1
• Metformin works by increasing insulin sensitivity, which complements sitagliptin's mechanism of increasing incretin levels, creating a synergistic effect 3

First-Line Addition: Metformin

• The combination of metformin with DPP-4 inhibitors like sitagliptin has been shown to be effective in clinical trials, with the VERIFY trial demonstrating that early combination therapy leads to better sustained glycemic control 3

Alternative Options Based on Patient Characteristics

• For patients with established cardiovascular disease or high risk, SGLT2 inhibitors or GLP-1 receptor agonists should be prioritized as add-on therapy to sitagliptin, offering additional benefits beyond glucose control, including cardiovascular risk reduction and renal protection 2, 4
• For patients with significant hyperglycemia (HbA1c levels >9%), consider more potent agents like GLP-1 receptor agonists or basal insulin 4, 3

Efficacy Considerations

• Each new class of non-insulin agents added to therapy generally lowers HbA1c by approximately 0.7-1.0% 3

Safety Considerations

• SGLT2 inhibitors and GLP-1 receptor agonists have a low risk of hypoglycemia when combined with sitagliptin 2, 4

Treatment Algorithm

• If the patient is not already on metformin, add metformin as the first choice, as recommended by the American Diabetes Association 1, 3
• For patients with established cardiovascular disease, heart failure, or chronic kidney disease, add an SGLT2 inhibitor or GLP-1 receptor agonist 2, 4
• For patients with severe hyperglycemia (HbA1c >9%), consider GLP-1 receptor agonist or basal insulin 4, 3

Important Monitoring Considerations

• Review medication response at regular intervals, assessing both efficacy (HbA1c, weight) and safety, as recommended by the American Diabetes Association 4